In this study we have demonstrated the feasibility of using [18 F]FDG-PET imaging as an early surrogate endpoint for monitoring biological and anti-tumor activity of MEK/Raf inhibitors given for the treatment of human cancers. This evidence concerns the gene MAP2K7 and neoplasm.